Publications 2004

Bakkus M.H., Bouko Y., Samson D., Apperley J.F., Thielemans K., Camp B.V., Benner A., Goldschmidt H., Moos M., Cremer F.W.: Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Brit.J.Haematol. 126 (5) 665-674, 2004.

Beyer S., Kröger M., Kopp-Schneider A., Ittrich C.: Identification of carcinogen induced changes in rat liver proteom by analysing SELDI-TOF spectra: a statistical approach. Statistical Computing Schloß Reisensburg, Günzburg, Germany, 2004.

Breitkreutz I., Benner A., Cremer F.W., Glasmacher A., Schmidt-Wolf I.G.D., Martin H., Hölzer M., Salwender H., Ho A.D., Goldschmidt H.: Thalidomide in first line treatment of multiple myeloma: no increase of severe adverse events. Onkol. 27(S3), p.185(P775), 2004.

Burkholder I., Laack E., Winkler C., Edler L.: Methods to assess quality of life in a randomised phase III study of gemcitabine + vinorelbine versus gemcitabine + vinorelbine + cisplatin in metastatic non-small cell lung cancer. J.Cancer Res.Clin.Oncol. 130(Suppl. 1), p.179 (PO820), 2004.

Butkiewicz D., Popanda O., Risch A., Edler L., Dienemann H., Schulz V., Kayser K., Drings P., Bartsch H., Schmezer P.: Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidem.Biomark.Prevent. 13 (12) 2242-2246, 2004.

Combs S.E., Schultz-Ertner D., Thilmann C., Edler L., Debus J.: Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther.Onkol. 180 (9) 590-596, 2004.

Combs S.E., Edler L., ., Debus J., Schultz-Ertner D.: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Radiother.Oncol. 73(Suppl.), p.S255-S256, 2004.

Combs S.E., Schultz-Ertner D., Thilmann C., Edler L., Debus J.: Treating cerebral metastases from breast cancer with stereotactic radiosurgery. J.Cancer Res.Clin.Oncol. 130(Suppl. 1), p.132 (PO614), 2004.

Dally H., Bartsch H., Jäger B., Edler L., ., Schmezer P., Spiegelhalder B., Dienemann H., Drings P., Kayser K., Schulz V., Risch A.: Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 207 (1) 95-99, 2004.

Deichmann M., Polychronidis M., Benner A., Kleist C., Thome M., Kahle B., Helmke B.M.: Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. Int.J.Oncol. 25 (2) 259-268, 2004.

Deichmann M., Thome M., Benner A., Näher H.: B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncol. 66 (5) 411-419, 2004.

Deichmann M., Kahle B., Benner A., Thome M., Helmke B., Näher H.: Somatic mitochondrial mutations in melanoma resection specimens. Int.J.Oncol. 24 (1) 137-141, 2004.

Demjen D., Klussmann S., Kleber S., Zuliani C., Stieltjes B., Metzger C., Hirt U.A., Walczak H., Falk W., Essig M., Edler L., Krammer P.H., Martin-Villalba A.: Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat.Med. 10 (4) 389-395, 2004.

Dreger P., Stilgenbauer S., Benner A., Ritgen M., Kröber A., Kneba M., Schmitz N., Döhner H.: The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on on the VH gene mutational status. Blood 103 (7) 2850-2858, 2004.

Edler L.: Zeigt Mistel eine komplementäre therapeutische Wirksamkeit? Die Studienlage zur Misteltherapie. InFoOnkologie 7 (3) 230-236, 2004.

Edler L.: Biometrie und Datenmanagement in klinischen Studien. Fortschr.Röntgenstr. 176(S1), p.S69(WS425.4), 2004. Stuttgart, Thieme.

Edler L.: Schlusswort zu Leserbrief Prof. Dr. B. Schneider (Chemotherapie mit komplementärer Misteltherapie. Wie evident ist ihre Wirksamkeit wirklich?) Internist.Prax. 44 (3) 658-660, 2004.

Edler L.: Book review: Niels Keiding. Biostatistical methods. S.W. Looney (ed), Human Press, Totowa, New Jersey, USA, 2002 Stat.Med. 23 (22) 3557-3559, 2004.

Edler L., Heinzl H., Mittlböck M.: Carrying-over toxicokinetic model uncertainty into cancer risk estimates: the TCCD example. Organohalogen Comp. 66 3356-3362, 2004.

Edler L.: Schlusswort zu Beitrag: Mistel in der Krebstherapie (Heft 1-2/2004). Dtsch.Ärztebl. 101 (30) A2126-A2127, 2004.

Edler L., Tritscher A.: Toxikodynamische Modelle. In: F.X.Reichl, M.Schwenk (Eds.), Regulatorische Toxikologie. Springer, Berlin, 2004, pp.209-215.

Edler L.: Mistel in der Krebstherapie. Dtsch.Ärztebl. 101 (1-2) A44-A49, 2004.

Edler L., Becker N.: Extrapolationsverfahren für kanzerogene und nicht-kanzerogene Stoffe. In: F.X.Reichl, M.Schwenk (Eds.), Regulatorische Toxikologie. Springer, Berlin, 2004, pp.192-202.

Edler L.: Limits of causality in non-randomized studies. Two sources of bias characterized in the counterfactual model. Biometr.J. 46(Suppl.1), p.12 (S05.3), 2004.

Felder B., Radlwimmer B., Klauck S.M., Benner A., Mincheva A., Poustka F., Lichter P., Poustka A.: Detection of submicroscopic chromosomal deletions and duplications in autism patients by matrix comparative genomic hybridisation (matrix-CGH). Am.J.Med.Genet. 130B(1), pp.91-92, 2004.

Fröhling S., Schlenk R.F., Stolze I., Bihlmayr J., Benner A., Kreitmeier S., Tobis K., Döhner H., Döhner K.: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J.Clin.Oncol. 22 (4) 624-633, 2004.

Görisch S.M., Wachsmuth M., Ittrich C., Bacher C.P., Rippe K., Lichter P.: Nuclear body movement is determined by chromatin accessibility and dynamics. PNAS 101 (36) 13221-13226, 2004.

Görisch S.M., Wachsmuth M., Bacher C.P., Ittrich C., Rippe K., Lichter P.: Nuclear body movement is determined by chromatin accessibility and dynamics. Europ.J.Cell Biol. 83(Suppl. 54), p.58, 2004.

Groos J., Kopp-Schneider A.: Visualization of parametric carcinogenesis models. Antoch J. pp.189-197, 2004. Heidelberg, Physica. COMPSTAT. Proceedings in Computational Statistics.

Helfrich I., Chen M., Schmidt R., Fürstenberger G., Kopp-Schneider A., Trick D., Gröne H.J., zur Hausen H., Rösl F.: Increased incidence of squamous cell carcinomas in mastomys natalensis papillomavirus E6 transgenic mice during two-stage skin carcinogenesis. J.Virol. 78 (9) 4797-4805, 2004.

Helmke B.M., Polychronidis M., Benner A., Thome M., Arribas J., Deichmann M.: Melanoma metastasis is associated with enhanced expression of the syntenin gene. Oncol.Rep. 12 (2) 221-228, 2004.

Helmke B.M., Mollenhauer J., Herold-Mende C., Benner A., Thome M., Gassler N., Wahl W., Lyer S., Poustka A., Otto H.F., Deichmann M.: BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. Gastroenterol. 127 (6) 1815-1820, 2004.

Hildebrandt W., Hamann A., Krakowski-Roosen H., Kinscherf R., Dugi K., Sauer R., Lacher S., Nöbel N., Bodens A., Bellou V., Edler L., Nawroth P., Dröge W.: Effect of thiol antioxidant on body fat and insulin reactivity. J.Mol.Med. 82 (5) 336-344, 2004.

Hothorn T., Lausen B., Benner A., Radespiel-Tröger M.: Bagging survival trees. Stat.Med. 23 (1) 77-91, 2004.

Ittrich C., Kopp-Schneider A.: Statistical analysis of carcinogen induced changes in the expression profile of rat liver genome and proteome. Biometr.J. 46(Suppl.1), p.4 (S02.3), 2004.

Ittrich C., Benner A., Edler L.: Evaluating the prognostic as well as the predictive value of gene-signatures in cancer clinical trials. Kooperative Versorgung, Vernetzte Forschung, Ubiquitäre Information. Meeting Abstracts(49. Jahrestagung GMDS), pp.337-338, 2004.
http://www.egms.de

Ittrich C., Scholz G., Ellinger-Ziegelbauer H., Ahr H.J., Hellmann J., Kopp-Schneider A.: Statistical issues in the analysis of changes in the gene expression profile of rat liver induced by n-nitrosomorpholine. Naunyn-Schmiedeb.Arch.Pharmacol. 369(Suppl.1), p.R133 (530), 2004.

Jeremias I., Steiner H.H., Benner A., Debatin K.M., Herold-Mende C.: Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir. 146 (7) 721-729, 2004.

Jhavar S., Sarin R., Mulherkar R., Benner A., Prakash Agarwal J., Dinshaw K.: Glutathione S-transferase M1 or T1 null genotype as a risk factor for developing multiple primary neoplasms in the upper aero-digestive tract, in Indian males using tobacco. Oral Oncol. 40 (1) 84-91, 2004.

Kienle D., Korz C., Hosch B., Benner A., Habermann A., Kröber A., Lichter P., Döhner H., Stilgenbauer S.: Evidence for distinct pathomechanisms in genetic subgroups of CLL by quantitative expression analysis of cell cycle-, activation-, and apoptosis-associated genes. Onkol. 27(S3), p.55 (O417), 2004.

Kim B.S., Edler L., Park J.J., Fournier D.v., Haase W., Sautter-Bihl M.L., Hagmüller E., Gotzes F., Thielmann H.W.: Exploitation of the dose/time-response relationship for a new measure of DNA repair in the single-cell gel electrophoresis (comet) assay. J.Toxicol.Pub.Hlth. 20 (2) 89-100, 2004.

Klauck S.M., Schuster C., Felder B., Beyer K.S., Benner A., Gohlke H., Illig T., Poustka F., Poustka A.: Autism: search for susceptibility variants in the German patient sample. Am.J.Med.Genet. 130B(1), p.91, 2004.

Koch M., Kienle P., Sauer P., Willecke F., Buhl K., Benner A., Lehnert T., Herfarth C., v.Knebel-Doeberitz M., Weitz J.: Hematogenous tumor cell dissemination during colonoscopy for colorectal cancer. Surg.Endosc. 18 (4) 587-591, 2004.

Kopp-Schneider A., Oberemm A., Herzig A., Richter-Reichhelm H.B., Gundert-Remy U., Kalenberg K., Krause A., Kröger M., Fella K., Hellmann J., Krammer P.J., Glückmann M., Ittrich C.: Statistical issues in the analysis of n-nitrosomorpholine induced changes in the expression profile of rat liver proteom. Naunyn-Schmiedeb.Arch.Pharmacol. 369(Suppl.1), p.R133 (532), 2004.

Kröger M., Beyer S., Fella K., Glückmann M., Kopp-Schneider A., Ittrich C., Kramer P.J.: SELDI approaches for liver cancer analysis. 12.Kongress über Alternativen zu Tierversuchen, Linz, Schweiz , 2004.

Laack E., Dickgreber N., Müller T., Knuth A., Benk J., Lorenz C., Gieseler F., Dürk H., Engel-Riedel W., Dalhoff K., Kortsik C., Graeven U., Burk M., Dierlamm T., Welte T., Burkholder I., Edler L., Hossfeld D.K.: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J.Clin.Oncol. 22 (12) 2348-2356, 2004.

Leo E., Scheuer L., Schmidt-Wolf I.G.D., Kerowgan M., Schmitt C., Leo A., Baumbach T., Krämer A., Mey U., Benner A., Parwaresch R., Ho A.D.: Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur.J.Haematol. 73 (4) 251-257, 2004.

Liebisch P., Wendl C., Scheck D., Wellmann A., Erne S.A., Tschajka K., Kirschenlohr M., Straka C., Goldschmidt H., Einsele H., Benner A., Döhner H.: Pathogenetic relevance and prognostic value of genomic imbalances in clonal plasma cell disorders. Onkol. 27(S3), p.32 (O175), 2004.

Lyko F., Stach D., Benner A., Stilgenbauer S., Döhner H., Wirtz M., Wiessler M., Schmitz O.J.: Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis 25 (10-11) 1530-1535, 2004.

Michaely H.J., Schönberg S.O., Ittrich C., Dikow R., Bock M., Günther M.: Renal disease: value of functional magnetic resonance imaging with flow and perfusion measurements. Invest.Radiol. 39 (11) 698-705, 2004.

Mönnikes O., Löppen S., Buchmann A., Andersson P., Ittrich C., Pöllinger L., Schwarz M.: A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64 (14) 4707-4710, 2004.

Mönnikes O., Löppen S., Buchmann A., Andersson P., Ittrich C., Pöllinger L., Schwarz M.: A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Naunyn-Schmiedeb.Arch.Pharmacol. 369(Suppl.1), p.R130 (517), 2004.

Müller A., Thatcher N., Kortsik C., Koschel G., Spengler W., Pilz L., Mezger J., Manegold C.: A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first-line combination versus sequential gemcitabine and docetaxel: second interim study results. J.Clin.Oncol. 22(Suppl.), p.14S (Abstr.No.7095), 2004.

Müller A., Thatcher N., Kortsik C., Koschel G., Spengler W., Pilz L., Manegold C.: Results of the first interim analysis of a randomised phase II/III in advanced non small cell lung cancer (NSCLC) study with first line combination versus sequential docetaxel and gemcitabine indicate effective treatment. J.Cancer Res.Clin.Oncol. 130(Suppl. 1), p.77 (PU370), 2004.

Müller A., Thatcher N., Kortsik C., Koschel G., Spengler W., Pilz L., Mezger J., Manegold C.: A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first-line combination versus sequential gemcitabine and docetaxel: second interim study results. Ann.Oncol. 15(Suppl.3), p.636PD, 2004.

Neben K., Korshunov A., Benner A., Wrobel G., Hahn M., Kokocinski F., Golanov A., Joos S., Lichter P.: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 64 (9) 3103-3111, 2004.

Oberemm A., Meckert C., Brandenburger L., Herzig A., Kalenberg K., Krause E., Scholz G., Ellinger-Ziegelbauer H., Ahr H.J., Ittrich C., Kopp-Schneider A., Hellmann J., Kramer P.J., Richter-Reichhelm H.B., Gundert-Remy U.: Analysis of global gene and protein expression during rat liver carcinogenesis induced by the genotoxic model carcinogen n-nitrosomorpholine. Naunyn-Schmiedeb.Arch.Pharmacol. 369(Suppl.1), p.R133 (529), 2004.

Popanda O., Schattenberg T., Phong C.T., Butkiewicz D., Risch A., Edler L., Kayser K., Dienemann H., Schulz V., Drings P., Bartsch H., Schmezer P.: Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogen. 25 (12) 2433-2441, 2004.

Risch A., Dally H., Tüngerthal S., Drings P., Fischer J., Edler L., Jäger B., Schmezer P., Spiegelhalder B., Bartsch H.: Association of XRCC-1 genotype with chemotherapy response in lung cancer patients. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R137 (569), 2004.

Schlenk R.F., Fröhling S., Hartmann F., Fischer J.T., Glasmacher A., del Valle F., Grimminger W., Götze K., Waterhouse C., Schoch R., Pralle H., Mergenthaler H.G., Hensel M., Koller E., Kirchen H., Preiss J., Salwender H., Biedermann H.G., Kremers S., Griesinger F., Benner A., Addamo B., Döhner K., Haas R., Döhner H.: Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukem. 18 (11) 1798-1803, 2004.

Schlenk R.F., Benner A., Krauter J., Buchner T., Sauerland C., Ehninger G., Schaich M., Mohr B., Niederwieser D., Krahl R., Pasold R., Döhner K., Ganser A., Döhner H., Heil G.: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. J.Clin.Oncol. 22 (18) 3741-3750, 2004.

Schlenk R.F., Benner A., Krauter J., Büchner T., Sauerland C., Ehninger G., Schaich M., Mohr B., Niederwieser D., Krahl R., Pasold R., Döhner K., Ganser A., Döhner H., Heil G.: Prognosis of patients with core binding factor acute myeloid leukemia after relaps - results of the original data based meta-analysis of the German AML-intergroup. Onkol. 27(S3), p.12 (O89), 2004.

Schlenzka J., Möhler T.M., Kipriyanov S.M., Kornacker M., Benner A., Bahre A., Stassar M.J.J.G., Schäfer H.J., Little M., Goldschmidt H., Cochlovius B.: Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15 (9) 915-919, 2004.

Stahl S., Ittrich C., Marx-Stölting P., Buchmann A., Schwarz M.: Microarray analysis of phenobarbital-induced gene expression in liver of connexin32-wildtype and connexin32-null mice. Naunyn-Schmiedeb.Arch.Pharmacol. 369(Suppl.1), p.R129 (516), 2004.

Windeler J., Antes G., Edler L.: Vom Irrtum mit den Wahrscheinlichkeiten. Dtsch.Ärztebl. 101 (34/35) A2310-A2311, 2004.

Winter H., Schissel D., Parry D.A.D., Smith T.A., Liovic M., Birgitte Lane E., Edler L., Langbein L., Jave-Suarez L.F., Rogers M.A., Wilde J., Peters G., Schweizer J.: An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J.Invest.Dermatol. 122 (3) 652-657, 2004.

Witzens M., Heilmann C., Hensel M., Benner A., Haas R., Frühauf S., Ho A.D.: Long term follow up of patients with non-Hodgkin's lymphoma treated with CD34+ selection of autologous transplants following myeloablative therapy. Onkol. 27(S3), p.171 (P731), 2004.

Witzens M., Hensel M., Schmier J.W., Benner A., Krämer A., Ho A.D.: Rituximab maintenance therapy in patients with CD20+ B-cell non-Hodgkin's-lymphoma. Onkol. 27(S3), p.134 (P601), 2004.

to top